1. Home
  2. RGCO vs SERA Comparison

RGCO vs SERA Comparison

Compare RGCO & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGCO
  • SERA
  • Stock Information
  • Founded
  • RGCO 1912
  • SERA 2008
  • Country
  • RGCO United States
  • SERA United States
  • Employees
  • RGCO N/A
  • SERA N/A
  • Industry
  • RGCO Oil & Gas Production
  • SERA Precision Instruments
  • Sector
  • RGCO Utilities
  • SERA Health Care
  • Exchange
  • RGCO Nasdaq
  • SERA Nasdaq
  • Market Cap
  • RGCO N/A
  • SERA 208.7M
  • IPO Year
  • RGCO N/A
  • SERA 2021
  • Fundamental
  • Price
  • RGCO $20.36
  • SERA $4.10
  • Analyst Decision
  • RGCO
  • SERA
  • Analyst Count
  • RGCO 0
  • SERA 0
  • Target Price
  • RGCO N/A
  • SERA N/A
  • AVG Volume (30 Days)
  • RGCO 10.7K
  • SERA 113.4K
  • Earning Date
  • RGCO 04-30-2025
  • SERA 05-07-2025
  • Dividend Yield
  • RGCO 4.07%
  • SERA N/A
  • EPS Growth
  • RGCO N/A
  • SERA N/A
  • EPS
  • RGCO 1.17
  • SERA N/A
  • Revenue
  • RGCO $87,511,366.00
  • SERA $94,000.00
  • Revenue This Year
  • RGCO $7.25
  • SERA N/A
  • Revenue Next Year
  • RGCO $5.62
  • SERA $3,081.82
  • P/E Ratio
  • RGCO $17.21
  • SERA N/A
  • Revenue Growth
  • RGCO N/A
  • SERA N/A
  • 52 Week Low
  • RGCO $18.38
  • SERA $3.84
  • 52 Week High
  • RGCO $24.20
  • SERA $12.36
  • Technical
  • Relative Strength Index (RSI)
  • RGCO 50.54
  • SERA 36.60
  • Support Level
  • RGCO $19.97
  • SERA $3.91
  • Resistance Level
  • RGCO $20.94
  • SERA $4.34
  • Average True Range (ATR)
  • RGCO 0.59
  • SERA 0.24
  • MACD
  • RGCO 0.02
  • SERA 0.10
  • Stochastic Oscillator
  • RGCO 67.36
  • SERA 28.44

About SERA Sera Prognostics Inc.

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.

Share on Social Networks: